NCT02569125View on ClinicalTrials.gov

Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions
Segmental Overgrowth Syndrome
Interventions
DRUG

Everolimus

4.5 mg/m² daily

Trial Locations (4)

12351

Vivantes Klinikum Neukölln, Berlin

53113

Universitätsklinikum Bonn, Bonn

79106

Universitätsklinikum Freiburg, Freiburg im Breisgau

04103

Universitätsklinikum Leipzig, Leipzig

Sponsors
All Listed Sponsors
collaborator

Clinical Trials Unit Freiburg

OTHER

lead

Jochen Roessler

OTHER